An Inhibitor of Glucosylceramide Synthase Inhibits the Human Enzyme, but Not Enzymes from Other Organisms

Specific inhibitors of glucosylceramide biosynthesis are used as drugs for the treatment of some human diseases correlated to glycosphingolipid metabolism. The target of the presently available inhibitors is the human glucosylceramide synthase (GCS), but effects on enzymes from other organisms have not been studied. We expressed cDNAs encoding GCS enzymes from lower animals, plants, fungi, and bacteria in the yeast P. pastoris. In vitro GCS assays with the GCS inhibitor D-threo-1-(3′,4′-ethylenedioxy)phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol showed that this inhibitor did not affect non-human GCS enzymes.

[1]  E. F. Merino,et al.  Glycosphingolipids in Plasmodium falciparum. Presence of an active glucosylceramide synthase. , 2004, European journal of biochemistry.

[2]  J. Kok,et al.  Sphingolipid metabolism enzymes as targets for anticancer therapy. , 2004, Current drug targets.

[3]  R. Kolesnick,et al.  Ceramide synthesis and metabolism as a target for cancer therapy. , 2004, Cancer letters.

[4]  L. Oland,et al.  New PDMP analogues inhibit process outgrowth in an insect cell line. , 2004, Bioorganic & medicinal chemistry letters.

[5]  G. Andria,et al.  The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: A position statement , 2003, Journal of Inherited Metabolic Disease.

[6]  S. Hakomori.  Cell adhesion/recognition and signal transduction through glycosphingolipid microdomain , 2000, Glycoconjugate Journal.

[7]  E. Heinz,et al.  Formation of glucosylceramide and sterol glucoside by a UDP‐glucose‐dependent glucosylceramide synthase from cotton expressed in Pichia pastoris , 2003, FEBS letters.

[8]  R. Proia.  Glycosphingolipid functions: insights from engineered mouse models. , 2003, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[9]  K. Sandhoff,et al.  Biosynthesis and degradation of mammalian glycosphingolipids. , 2003, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[10]  J. Shayman,et al.  Disruption of the glucosylceramide biosynthetic pathway in Aspergillus nidulans and Aspergillus fumigatus by inhibitors of UDP‐Glc:ceramide glucosyltransferase strongly affects spore germination, cell cycle, and hyphal growth , 2002, FEBS letters.

[11]  B. Westerink,et al.  UvA-DARE ( Digital Academic Repository ) Glycosphingolipids are required for sorting melanosomal proteins in the Golgi complex , 2001 .

[12]  E. Heinz,et al.  Glucosylceramide Synthases, a Gene Family Responsible for the Biosynthesis of Glucosphingolipids in Animals, Plants, and Fungi* , 2001, The Journal of Biological Chemistry.

[13]  A. Abe,et al.  Improved inhibitors of glucosylceramide synthase. , 1992, The Journal of biological chemistry.

[14]  R. Dwek,et al.  N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. , 1994, The Journal of biological chemistry.

[15]  N. Radin,et al.  Metabolic effects of inhibiting glucosylceramide synthesis with PDMP and other substances. , 1993, Advances in lipid research.

[16]  A. Merrill.  Ceramide: a new lipid "second messenger"? , 2009, Nutrition reviews.